A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

Cite this paper

@article{Atzori2011API, title={A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.}, author={Francesco Atzori and Josep Tabernero and Andr{\'e}s Cervantes and Ludmila Prudkin and Jordi Andreu and Edith Rodr{\'i}guez-Braun and Amparo Domingo and Jorge Guijarro and Cristina Gamez and Jordi Rodon and Serena Di Cosimo and Holly Brown and Jason Clark and James S Hardwick and Robert A Beckman and William D Hanley and Karl Hsu and Emiliano Calvo and Susana Rosell{\'o} and Ronald B Langdon and Jos{\'e} Baselga}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2011}, volume={17 19}, pages={6304-12} }